Business
10x Genomics Appoints Kim Popovits to Board of Directors
Former Genomic Health CEO brings decades of healthcare experience to Board PLEASANTON, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq:
About this update from 10x Genomics, Inc.
[{"type":"text","content":"Former Genomic Health CEO brings decades of healthcare experience to Board\nPLEASANTON, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today announced the appointment of Kim Popovits, former Chairman of the Board, President and Chief Executive Officer of Genomic Health, Inc., to the company’s Board of Directors. She brings decades of experience in scaling organizations, building global operations and advancing innovations in both the diagnostics and pharmaceutical industries. \n “Kim has been a leader and a pioneer in introducing new technologies into the healthcare system impacting the lives of countless patients during her time at Genomic Health and Genentech,” said Serge Saxonov, co-founder and CEO of 10x Genomics. “Today, more than ever, we need to enable scientists to make discoveries that will lead to better patient outcomes, and we are excited to have Kim join the Board to accelerate our efforts.” Kim arrived at Genomic Health in 2002 as President and Chief Operating Officer, before becoming CEO in 2009 and Chairman of the Board in 2012. Under her leadership, Genomic Health became the industry leader in genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer, resulting in an acquisition by Exact Sciences (Nasdaq: EXAS) in November 2019. Prior to joining Genomic Health, Kim held several management roles at Genentech, Inc. including Senior Vice President of Marketing and Sales where she led the commercialization of 14 new therapies in the biotechnology industry. Before Genentech, Kim was at American Critical Care, a Division of American Hospital Supply, a supplier of healthcare products to hospitals. “I am excited to be joining a team that is leading the advancement of science at a pace that will transform clinical practice and lead to better outcomes for patients,” said Popovits. “The track record of the 10x team in delivering innovations to our industry is impressive and I look forward to applying my background towards enhancing the continued success of the company.” In addition to her Board position at 10x Genomics, Kim is a current member of the Boards of Directors for Kiniksa Pharmaceuticals, Ltd. and MyoKardia, Inc., and previously served on the Board of ZS Pharma Inc. About 10x Genomics10x Genomics is a life science technology company building pr...